Natural Killer Cells and Cancer Therapy
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (15 November 2018) | Viewed by 112213
Special Issue Editors
Interests: Natural Killer cells; immunotherapy; signal transduction; cell migration; lymphocyte reactivity
Special Issue Information
Dear Colleagues,
Immunotherapy is rapidly developing for many cancers and will certainly become the mainstay of treatment under various conditions. Current immunotherapies target T cells and are designed to promote or restore their activities by blocking immune checkpoints (ICP), such as PD-1. Yet, other effector cells, such as Natural Killer (NK) cell, are endowed with a strong and specific anti-tumor potential that could be harnessed, with perhaps less collateral damage (auto-immunity or immunopathology). NK cells express dedicated receptors that allow them to recognize a broad range of tumor cells of various origins. Upon activation, they can kill target cells and release IFNg and other factors that contribute to tumor elimination and control of metastatic dissemination. NK cell-based therapies are under investigation in patients and include for example antibodies blocking inhibitory NK cell receptors, bispecific antibodies triggering NK cell activation, cytokines boosting NK cell cytotoxic potential, or infusions of in vitro activated NK cells expressing or not chimeric-antigen receptors. Such strategies could be combined to more conventional therapies (chemotherapies, radiotherapy, etc.) to increase their success rate. Enhancement of NK cell activity is especially needed in cases of tumor relapse after ICP blockade, a situation often associated with the loss of MHC-I expression. As NK cells are sensitive to exhaustion strategies to avoid or reverse NK cell exhaustion should also be designed. This series of articles reviews the current literature on NK cells and cancer therapy, from basic conceptual aspects to clinical applications.
Dr. Thierry Walzer
Dr. Sebastien Viel
Dr. Antoine Marçais
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.